Kraj: Kanada
Język: angielski
Źródło: Health Canada
HYDROMORPHONE HYDROCHLORIDE
TEVA CANADA LIMITED
N02AA03
HYDROMORPHONE
4MG
TABLET
HYDROMORPHONE HYDROCHLORIDE 4MG
ORAL
100
Narcotic (CDSA I)
OPIATE AGONISTS
Active ingredient group (AIG) number: 0108698006; AHFS:
APPROVED
2011-01-18
Teva-HYDROmorphone Page 1 of 37 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION N TEVA-HYDROMORPHONE (HYDROMORPHONE HYDROCHLORIDE TABLETS, USP) Tablets: 1 mg, 2 mg, 4 mg and 8 mg, Oral Opioid Analgesic Teva Canada Limited 30 Novopharm Court Toronto, Ontario M1B 2K9 www.tevacanada.com Submission Control No.: 244765 Date of Revision: Nov 13, 2020 Teva-HYDROmorphone Page 2 of 37 RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS Neurologic, Serotonin toxicity / Serotonin syndrome NOV, 2020 7 WARNINGS AND PRECAUTIONS, Respiratory, Sleep Apnea NOV, 2020 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES ....................................................................................... 2 TABLE OF CONTENTS ............................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION ................................................................ 4 1 INDICATIONS .................................................................................................................... 4 1.1 Pediatrics ..................................................................................................................... 4 1.2 Geriatrics ...................................................................................................................... 4 2 CONTRAINDICATIONS ..................................................................................................... 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX .......................................................... 5 4 DOSAGE AND ADMINISTRATION ................................................................................... 6 4.1 Dosing Considerations ................................................................................................. 6 4.2 Recommended Dose and Dosage Adjustment ............................................................. 6 4.3 Administration ..................... Przeczytaj cały dokument